In Kenya, a retrospective analysis of HPV Dose 1 data from the national health information system (2019–2025) reveals a pronounced cyclical uptake pattern, with quarterly doses ranging from a low of 21,764 (Q1 2025) to a peak of 564,403 (Q4 2021), with surges consistently linked to intensified outreach campaigns and school calendar alignment and sharp inter-campaign troughs reflecting the limitations of routine facility-only delivery. The COVID-19 pandemic caused a steep early decline, while recovery from 2021 onward was driven by multi-age cohort campaigns and renewed outreach support, with mid-2024 big catch-up activities reaching 335,249 doses before a further decline to 186,066 in Q2 2025. Kenya adopted the single-dose schedule in 2024, with the transition offering efficiency gains and coverage expansion potential, contingent on consistent financing during the Gavi transition, institutionalised school outreach mechanisms, and strengthened health worker training. Reaching the WHO 90% coverage target by 2030 will require domestic resource mobilisation and sustained intersectoral collaboration between health, education, and county governments.